
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7753580/publications.pdf Version: 2024-02-01



IFFEREY I MOLLOREM

#	Article	IF	CITATIONS
1	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. Journal of Clinical Oncology, 2021, 39, 2710-2719.	1.6	32
2	Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia. Cytotherapy, 2021, 23, 793-798.	0.7	1
3	Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia, 2020, 34, 1626-1636.	7.2	9
4	Fidelity of peripheral blood for monitoring genomics and tumor immuneâ€microenvironment in myelodysplastic syndromes. EJHaem, 2020, 1, 552-557.	1.0	3
5	Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade. Blood, 2020, 136, 4-4.	1.4	0
6	Tumor-Associated Antigens. , 2019, , 107-125.		3
7	Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biology of Blood and Marrow Transplantation, 2019, 25, 1347-1354.	2.0	4
8	Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clinical Cancer Research, 2019, 25, 2610-2620.	7.0	23
9	Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity. Nature Communications, 2019, 10, 254.	12.8	120
10	Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clinical Cancer Research, 2018, 24, 3386-3396.	7.0	4
11	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Advances, 2018, 2, 2052-2062.	5.2	24
12	Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy, 2018, 20, 1089-1101.	0.7	13
13	Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation. Journal of Immunology, 2018, 201, 1389-1399.	0.8	30
14	A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2. Frontiers in Immunology, 2018, 9, 3153.	4.8	12
15	Targeting PR1 in myeloid leukemia. Oncotarget, 2018, 9, 4280-4281.	1.8	12
16	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research, 2017, 5, 319-329.	3.4	25
17	Interaction between Tumor Cell Surface Receptor RAGE and Proteinase 3 Mediates Prostate Cancer Metastasis to Bone. Cancer Research, 2017, 77, 3144-3150.	0.9	31
18	Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. Journal of Biological Chemistry, 2017, 292, 10295-10305.	3.4	41

#	Article	IF	CITATIONS
19	Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Research, 2017, 77, 5374-5383.	0.9	118
20	Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia, 2017, 31, 234-237.	7.2	30
21	Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target. Frontiers in Immunology, 2017, 8, 1975.	4.8	18
22	PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy, 2016, 18, 995-1001.	0.7	9
23	Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells. Cancer Immunology, Immunotherapy, 2016, 65, 741-751.	4.2	25
24	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood, 2016, 128, 297-312.	1.4	54
25	A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy, 2016, 18, 985-994.	0.7	77
26	Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E1555-64.	7.1	174
27	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS ONE, 2016, 11, e0160004.	2.5	33
28	Ibrutinib Treatment Modulates T Cell Activation and Polarization in Immune Response. Blood, 2015, 126, 3435-3435.	1.4	8
29	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood, 2015, 126, 854-854.	1.4	5
30	PAND: A Distribution to Identify Functional Linkage from Networks with Preferential Attachment Property. PLoS ONE, 2015, 10, e0127968.	2.5	1
31	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Translational Medicine, 2014, 3, 1435-1443.	3.3	75
32	A Novel HLA-A*0201 Restricted Peptide Derived from Cathepsin G Is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 247-257.	7.0	33
33	Breast Cancer Cell Uptake of the Inflammatory Mediator Neutrophil Elastase Triggers an Anticancer Adaptive Immune Response. Cancer Research, 2012, 72, 3153-3162.	0.9	77
34	Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. Journal of Immunology, 2012, 189, 5476-5484.	0.8	37
35	The Role of Antigen Cross-presentation From Leukemia Blasts on Immunity to the Leukemia-associated Antigen PR1. Journal of Immunotherapy, 2012, 35, 309-320.	2.4	37
36	Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood, 2011, 118, 2159-2169.	1.4	14

#	Article	IF	CITATIONS
37	An anti–PR1/HLA-A2 T-cell receptor–like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood, 2011, 117, 4262-4272.	1.4	105
38	Vaccines as consolidation therapy for myeloid leukemia. Expert Review of Hematology, 2011, 4, 37-50.	2.2	17
39	PML and PMLRARα Interact with Fas to Regulate Fas-Mediated Apoptosis In Vivo. Blood, 2011, 118, 2451-2451.	1.4	0
40	A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia. Blood, 2011, 118, 2986-2986.	1.4	0
41	Preparing Basic and Translational Grant Proposals: Thoughts from the Trenches. Hematology American Society of Hematology Education Program, 2010, 2010, 181-184.	2.5	2
42	Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy, 2010, 12, 1056-1062.	0.7	27
43	PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal. PLoS ONE, 2010, 5, e11770.	2.5	29
44	Cellular Uptake of Soluble Neutrophil Elastase Increases Cyclin E (CCNE) Isoform Expression and Significantly Augments Susceptibility of Breast Cancer Cells to Cytolysis by CCNE-Specific Cytotoxic T Lymphocytes. Blood, 2010, 116, 2090-2090.	1.4	0
45	Soluble Inflammatory Mediators Proteinase-3 and Neutrophil Elastase Are Targeted by PR1-Specific Immunotherapy After Cellular Uptake and Cross Presentation of PR1 Peptide by Breast Cancer Cells. Blood, 2010, 116, 2089-2089.	1.4	2
46	Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood, 2009, 114, 1958-1967.	1.4	235
47	Understanding and Enhancing the Graft-Versus-Leukemia Effect After Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, 2009, 144, 187-208.	0.5	3
48	Cytotoxic T Lymphocytes (CTL) Specific for CMV, Adenovirus, and EBV Can Be Generated From Naive T Cells for Adoptive Immunotherapy Blood, 2009, 114, 504-504.	1.4	0
49	Breaking Immune Tolerance to Granule Proteases with Full-Length Antigen Vaccine in Humanized Transgenic Mice Reveals Alternative Antigen Processing and Immunodominance Heirarchy Applicable to Clinical Immunotherapy Blood, 2009, 114, 2054-2054.	1.4	Ο
50	LFA-1 Regulates CD8 + T Cell Activation and Immune Signal Network Blood, 2009, 114, 1641-1641.	1.4	0
51	Genomics as a Tool for Antigen Discovery in Allogeneic Stem Cell Transplantation: Identification of the Minor Antigen T4A through Donor/Patient Polymorphism Disparities. Blood, 2008, 112, 3907-3907.	1.4	8
52	Direct Visualization of PR1/HLA-A2 on the Membrane of HLAA2+ CD13+CD33+ Myeloid Leukemia Blasts by a Novel Monoclonal Antibody. Blood, 2008, 112, 2545-2545.	1.4	0
53	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. Blood, 2008, 112, 5440-5440.	1.4	1
54	Regulatory and Nail̀^ve T Cells in Unmanipulated Donor Grafts Are Not Associated with Acute Graft Vs Host Disease in Matched Sibling Transplants for AML. Blood, 2008, 112, 719-719.	1.4	0

#	Article	IF	CITATIONS
55	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia Blood, 2007, 110, 283-283.	1.4	9
56	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival Blood, 2007, 110, 577-577.	1.4	5
57	T-Cell Autoimmunity May Contribute to Neutropenia in a Patient with Cyclic Neutropenia (CN) and Double De-Novo Mutations in Gfi-1 Blood, 2007, 110, 3298-3298.	1.4	0
58	Aberrant Subcellular Localization of Azurophil Granule Proteins in Myeloid Leukemia Favors Peptide Antigen Presentation on MHC-I and Susceptibility to Killing by Cytotoxic T Lymphocytes Blood, 2007, 110, 4900-4900.	1.4	0
59	Vaccination for Leukemia. Biology of Blood and Marrow Transplantation, 2006, 12, 13-18.	2.0	31
60	Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nature Medicine, 2006, 12, 1160-1166.	30.7	536
61	Delayed Immune Recovery after Umbilical Cord Blood Transplantation (UCBT) Is Characterized by Thymic Regeneration Failure Blood, 2006, 108, 312-312.	1.4	6
62	Characterization of optimal T Cell/Dendritic Cell (DC) Co-Culture Conditions for Ex Vivo Expansion of Antigen-Specific Human T Cells Blood, 2006, 108, 3654-3654.	1.4	19
63	Aberrantly Expressed Neutrophil Elastase (ELA2) Cleaves Cyclin E (CCNE) in the Nucleus and Cytoplasm of Acute Lymphocytic Leukemia Yielding Novel Leukemia-Associated Antigens Blood, 2006, 108, 4429-4429.	1.4	0
64	Pre-Existing Anti-GM-CSF Autoantibodies in Patients with AML, CML and MDS Are Associated with Compromised Immune Response to PR1 Peptide Vaccination Blood, 2005, 106, 3257-3257.	1.4	0
65	Two Cyclin-Dependent Kinase Derived Peptides Are Potential Leukemia-Associated-Antigens Able To Eradicate Acute Myeloid Leukemia Cells after Allogeneic Stem Cell Transplantation Blood, 2005, 106, 3103-3103.	1.4	0
66	Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia Blood, 2004, 104, 259-259.	1.4	47
67	Mitochondrial DNA (mtDNA) Sequence Heterogeneity among and within Single Human CD34 Cells, T Cells, B Cells and Granulocytes Blood, 2004, 104, 3217-3217.	1.4	0
68	Antigen Cross-Presentation Allows the PR1 Leukemia-Associated Antigen To Be Processed from Both Proteinase 3 and Neutrophil Elastase to Prime T Cells Blood, 2004, 104, 3245-3245.	1.4	0
69	High Avidity Cyclin E1-Derived Peptide-Specific CTL Kill Lymphoid Leukemia Cells and Cross-Recognize a Homologous Cyclin E2-Derived Peptide Blood, 2004, 104, 4498-4498.	1.4	0
70	Immunotherapy of Hematologic Malignancy. Hematology American Society of Hematology Education Program, 2003, 2003, 331-349.	2.5	67
71	Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. Journal of Clinical Investigation, 2003, 111, 639-647.	8.2	65
72	Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. Journal of Clinical Investigation, 2003, 111, 639-647.	8.2	189

#	Article	IF	CITATIONS
73	Overexpressed differentiation antigens as targets of graft-versus-leukemia reactions. Current Opinion in Hematology, 2002, 9, 503-508.	2.5	49
74	Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes. Annals of Internal Medicine, 2002, 137, 156.	3.9	196
75	The basis of T-cell-mediated immunity to chronic myelogenous leukemia. Oncogene, 2002, 21, 8668-8673.	5.9	9
76	Leukemia vaccines. Current Oncology Reports, 2001, 3, 193-200.	4.0	8
77	Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine, 2000, 6, 1018-1023.	30.7	651
78	Harnessing graftâ€versusâ€malignancy: nonâ€myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. British Journal of Haematology, 2000, 111, 18-29.	2.5	6
79	Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?. Seminars in Hematology, 2000, 37, 15-29.	3.4	148
80	Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units. Blood, 1997, 90, 2529-2534.	1.4	216
81	Antithymocyte globulin for patients with myelodysplastic syndrome. British Journal of Haematology, 1997, 99, 699-705.	2.5	262
82	Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen. British Journal of Haematology, 1996, 93, 606-612.	2.5	48